Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us. Read our opinion piece in @JCO_ASCO ascopubs.org/doi/full/10.120…

Wonderful editorial on treatment of bladder cancer in older adults - "The best surgeons know when not to cut; perhaps the best medical oncologists know and should advise when systemic anticancer treatment is not the best option" ascopubs.org/doi/full/10.120…

Do not ask your children to strive for extraordinary lives.

There’s an old Chinese proverb that I love: “He who blames others has a long way to go on his journey. He who blames himself is halfway there. He who blames no one has arrived.”

Neutropenic Diet is not an evidence based recommendation for most patients with cancer ascopubs.org/doi/abs/10.1200…

Would be great to embrace grief protocols in oncology. On the @BloodCancerUtd Podcast I’m making the case for bereavement care as standard. It's an important part of caring treatingbloodcancers.org/e12…

Steroid free antiemetic regimen in Phase III trial! Phase III (DESCEND, n=644): with NEtupitant/palonosetron (NEPA), a fixed-dose oral com- bination, improves CINV control + olanzapine as the shared backbone, both cutting dexamethasone to a single 6mg dose on day 1 and dropping it entirely were noninferior to standard 4-day DEX for CINV in highly emetogenic chemo. CR (complete response: no emesis, no rescue meds), 0-120h: 72.4% standard vs 72.2% DEX-sparing vs 70.1% DEX-free. Both met noninferiority, confirmed per-protocol. Steroid toxicity (insomnia, agitation, hiccups) dropped significantly in both reduced-DEX arms. @KlugmanMaddie Meng et al, JCO 2026 doi.org/10.1200/JCO.26-01029 #oncology #breastcancer #CINV

The 21st Century Cures Act made results instant. Nobody funded the conversation that follows. New @JCOOP_ASCO data: 1 patient message → 7 more. Invisible work is paid for in burnout. Oncologists need teams to support them ascopubs.org/doi/pdf/10.1200…

Washington's dream for healthcare (inspired by Nate Bargatze).

Steve Kerr says Roger Federer taught his Warriors team the secret to sustained success wasn’t outworking everyone, it was building a life around your craft you never want to escape from “I’ll tell you a great story about Roger Federer. We were playing in China with the Warriors in 2017. Roger was in Shanghai for the Masters tournament, so we invited him to come speak to the team.” “Draymond Green asked him, ‘How do you sustain success? How have you managed to win majors 20 years after you first won one?’ Everyone was expecting him to say, ‘I work harder than everybody,’ the will, all the clichés.” “Roger Federer says, ‘I get up every morning and I make breakfast for my kids. Then I take them to school and drop them off. Then I go practice tennis for about two hours, and I’ve figured out a really good routine where I don’t destroy my body, but I can get all the work in I need.” “‘Then I go have lunch with my wife. In the evening, we cook dinner together. The kids are all home from school. We ask them about school. There’s so much joy in the house. We put them to bed, and then I put my head on the pillow and go, “Man, that was just a great day.” And I’ve been doing that for 20 years.’” “And it was like, yes. That’s it. That’s the formula. That’s what leads to sustained success. He loves tennis. He loves his family. He loves life. It’s not outworking everybody and banging your head against the wall, ‘I’m going to be better than everybody.’ It’s allowing your natural talent to shine through with a work ethic, with a great family life, with perspective, with peace, with mindfulness.” “It’s perspective. It’s joy. It’s passion. It’s mindfulness. It’s an awareness that we are truly lucky. To get the most out of ourselves, it’s our daily rituals and experiences and love and joy.”

New, large analysis of T-DXd-related ILD from 🇯🇵. Among 2801 patients, 381 (14%) developed ILD with T-DXd, of which 30 (7.9%) fatal. Most cases (83%) recovered, and steroids helped — but neither high-dose steroids nor immunosuppressants helped in G3-4 ILD. academic.oup.com/oncolo/adva…

Less is sometimes more

I agree with the diagnosis in the article, but there’s a paradox it misses: academic medicine helps create the very problem it laments Yes, we underpay people relative to their value, then moralize about it. Leave for pharma? “The dark side.” Consult for industry? COI. Move to start up? Too aligned with payers. Negotiate aggressively? Not mission-driven enough or even worse have to answer to non-physician administrators Law, business, tech and politics accept that talented people seek compensation, influence, ownership, and value Maybe the problem is that we’ve built a culture where wanting to be fairly rewarded is treated as a character flaw or selfish

Beautifully written mansucript from @GlopesMd in @JAMAOnc re: how we can remain competitive in an evolving global landscape of #clincaltrials. Agree with all of the solutions proposed. I would add that we also need to refine the philosophy with which we open studies at our respective centers. Study portfolios should not "fill a checkerboard" of clinical scenarios, but rather should be built around areas of clinical strength in respective programs (e.g., if I see lots of pts for adjuvant tx and none for 1L tx, focus the study portfolio on adjuvant). I see many sites with overwhelming numbers of studies and underwhelming accrual. This bogs down the system in many ways. Dr. Lopes, thanks for initiating a terrific discussion!

The Prestige Paradox in Academic Medicine opmed.doximity.com/articles/… via @doximity #MedEd #academia #lcsm #lcam

$39,800 every 30 days for daraxonrasib. Nearly $480K for 12 fills. Pancreatic cancer takes work, independence, time & turns loved ones into unpaid caregivers We’ll pay extraordinary prices for the molecule. But still little for the people / families suffering from the illness

The results are truly a milestone✅️ However, if the price is as reported by The New York Times, access to the drug is likely to be a major challenge👇 nytimes.com/2026/08/26/scien…

"I don't want Jenny to think I'm abandoning her" - a viewpoint exploring why we overtreat in cancer capc.org/documents/download/…